Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | TACR2 | P21452 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TST | Q16762 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177117 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9154487 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL8496560 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL4810276 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL8702332 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9579598 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9253594 | 0.98 | ESR1 (0.63) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10986143 | 0.94 | RARB (0.58) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL4773858 | 0.93 | CA2 (0.54) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL8053812 | 0.92 | HSD17B10 (0.61) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219629-A | N-benzyl imidazopyridine derivative and preparation method and application thereof | 中国药科大学 | 2024-12-31 | — | — | CN | disclosed |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9629859-B2 | Nitric oxide donors | MEDICAL RESEARCH COUNCIL (NZ) | 2017-04-25 | — | — | US | disclosed |
| EP-0805134-B1 | NOVEL LIQUID-CRYSTAL COMPOUNDS BEARING DIENYL MOIETY AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORP (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6086964-A | Liquid crystalline compound having dienyl moiety and liquid crystal composition | CHISSO CORPORATION (JP) | 2000-07-11 | — | — | US | disclosed |
| US-6001275-A | LIQUID CRYSTALLINE COMPOUND WHICH HAS A LARGE RATIO OF ELASTIC CONSTANTS, HAS A LOW VISCOSITY, EXCELLENT MISCIBILITY WITH OTHER LIQUID CRYSTALLINE COMPOUND, CHEMICALLY STABLE; HAVING AN UNCONJUGATED ALKADIENYL GROUP AT A SIDE CHAIN. | CHISSO CORPORATION (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0805134-A1 | NOVEL LIQUID-CRYSTAL COMPOUNDS BEARING DIENYL MOIETY AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | ESR1 4518/4885ADRA2A 647/4885ADORA3 504/4885 |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | MCOLN1, CNR1, SLC5A7 | ESR1 4518/4885ADRA2A 647/4885ADORA3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.